Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00933621

Enrollment

Registered

2009-07-07

Start date

2003-04-30

Completion date

2003-12-31

Last updated

2009-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Ischemic Symptomatic Heart Failure

Brief summary

The study aim is to evaluate the long term outcome of intra-coronary autologous bone marrow (BM) transplantation in patients with severe ischemic cardiomyopathy without the option for revascularization.

Detailed description

Several studies have demonstrated the short term safety, feasibility and efficacy of cell transplantation in patients with advanced heart failure. There are no data about the long term outcome.

Interventions

PROCEDUREAutologous bone marrow intracoronary infusion

Percutaneous intracoronary mononuclear bone marrow cell infusion

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 88 Years

Healthy volunteers

Inclusion criteria

* Patients with evidence of hibernation and/or ischemia in at least 2 different myocardial segments underwent coronary angiography

Exclusion criteria

* Idiopathic or non-ischemic cardiomyopathy * Other etiology for heart failure, history of past or current disease involving the bone marrow * Patients on dialysis * Positive serologic test for HIV, hepatitis B or C or any neoplastic or terminal disease

Design outcomes

Primary

Measure	Time frame
Procedure success	9 months

Secondary

Measure	Time frame
Functional class improvement	9 months

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026